LivaNova (NASDAQ:LIVN) reported second-quarter results that surpassed Wall Street expectations, prompting the medical technology company to raise its earnings and revenue guidance for the full year. The stronger performance helped lift the shares around 1.3% in after-hours trading.
The company delivered adjusted earnings of $1.26 per share, beating the analyst consensus estimate of $1.09. Revenue rose to $390.6 million, ahead of the expected $380.57 million and up 10.8% from $352.5 million in the second quarter of 2025. On a constant-currency basis, revenue increased 9.8% year over year.
Full-year guidance moves higher
Following the stronger-than-expected quarter, LivaNova raised its adjusted diluted earnings per share guidance for 2026 to a range of $4.30 to $4.40, compared with its previous forecast of $4.20 to $4.30.
The midpoint of the revised guidance, $4.35 per share, is above the Wall Street consensus estimate of $4.25.
The company also lifted its constant-currency revenue growth outlook for the year to between 8% and 9%, an increase from its previous forecast of 7% to 8%.
Core businesses continue to drive growth
Chief Executive Officer Vladimir Makatsaria said the company’s key operating divisions continued to perform well during the quarter.
“In the second quarter, LivaNova delivered strong revenue growth driven by sustained performance in our Cardiopulmonary and Epilepsy businesses,” Makatsaria said. “Our updated 2026 guidance reflects strong execution in the core businesses as we advance our strategic plan and drive long-term value creation.”
The Cardiopulmonary division generated revenue of $221.6 million, an increase of 11.2% year over year, supported by growing sales of the Essenz Perfusion System in Europe, higher consumables demand and favourable pricing.
Neuromodulation revenue rose 10.1% to $166.9 million, benefiting from higher sales volumes and improved pricing across all geographic regions.
Supply agreement announced as cash flow outlook trimmed
LivaNova also announced a long-term agreement with Thermo Fisher Scientific aimed at strengthening the supply of oxygenator components while expanding manufacturing capacity.
Despite raising its earnings and revenue outlook, the company lowered its adjusted free cash flow guidance for 2026 to between $140 million and $160 million, down from its previous forecast of $160 million to $180 million.
Management said the reduction reflects additional strategic investment in manufacturing capacity, product innovation and information technology infrastructure to support future growth.
LivaNova stock price
